FDA to disclose advisors' financial ties

The FDA is planning to let some blue sky into its advisory committees. In an attempt to stifle conflicts of interest, the agency wants to tell the public about any advisory committee member's financial ties to the drug industry.

Now, experts who advise the agency on drugs and other products have to disclose these financial relationships. If the FDA chooses to allow the expert onto the committee anyway, it has to announce that it's granted that person a waiver. But details of the financial relationships aren't shared. Last year, a study showed that a quarter of the advisory-committee experts had a financial conflict. Only 1 percent of them were excluded from serving.

- check out the FDA's release
- read the report from the Associated Press

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.